Tenax Therapeutics Inc. stocks have been trading down by -85.95 percent, reflecting mounting concern over its latest clinical developments.
Click Here for a Millionaire's POV on Trading TENX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- TENX has slid from recent highs above $16, with the latest close around the mid-$13s showing a steady pullback on the daily chart.
- Intraday action in TENX shows extreme volatility, including a premarket spike above $12 followed by a collapse toward $2.
- Tenax Therapeutics Inc. holds over $117M in cash and no debt, giving TENX meaningful runway despite heavy operating losses.
- TENX continues to post large negative earnings, signaling a high-risk biotech profile that active traders often target.
Live Update At 09:16:58 EDT: On Monday, August 10, 2026 Tenax Therapeutics Inc. stock [NASDAQ: TENX] is trending down by -85.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Tenax Therapeutics Inc., the company behind TENX, is a classic high-risk, high-reward biotech-style chart. The financials back that up. In the latest reported quarter ending 2026/06/30, Tenax recorded a net loss of about $17.8M and negative free cash flow of roughly $14.2M. That means TENX is burning cash to fund operations, mainly research and development, which ran near $12.9M for just one quarter.
At the same time, Tenax Therapeutics Inc. reported around $117.9M in cash and restricted cash on the balance sheet and zero debt. A current ratio above 15 shows TENX is very liquid in the near term, so the company is not fighting a balance sheet fire right now. Return on equity and return on assets are deeply negative, highlighting that the business is far from profitable.
More Breaking News
- Archer Aviation Stock Surges As AI, Defense, And Midnight Milestones Hit
- RKT Stock Slides As Guidance Tempers Rocket Companies’ Breakout Quarter
- YJ Surges As Yunji Inc. Delivers Extreme Price Spike
- Microchip Technology Surges After Earnings Beat And Raised Guidance
On valuation, the price‑to‑book ratio near 4.4 tells traders that TENX trades at a premium to its equity base, typical for speculative biotech names. With earnings per share at about -$0.35 for the quarter and cash flow still negative, TENX remains a story of runway plus potential, not current profits.
Why Traders Are Watching TENX Price Action
TENX has given active traders exactly what they look for: volatility, clear levels, and emotion on the tape. On the daily chart, Tenax Therapeutics Inc. has pulled back from the 16–17 area earlier in the period to recent closes around $13–14. That drop shows supply winning in the short term, but the stock is still well above some earlier support zones near $13, so the bigger trend is not completely broken.
Zoom in and TENX looks even wilder. The intraday five‑minute chart shows a premarket spike where prints hit the $12–13 range, then a brutal flush down into the low single digits around the $2 area. That type of gap and slam is textbook dilution, offering, or repricing action behaviorally, even when traders do not have the headline in front of them. For day traders, that’s a playground: wide ranges, big spreads, and plenty of opportunity if you manage risk.
From there, TENX settles into a tight band around $1.90–$2.10, showing consolidation after the shock move. When Tenax Therapeutics Inc. compresses like that following a huge intraday dump, experienced traders watch for the next expansion. A break over intraday highs can trigger short covering and sympathy momentum. A crack under the consolidation lows often leads to another leg down as bagholders bail.
Put it together and TENX sits at a crossroads. The daily downtrend, intraday volatility, and large cash cushion create a setup where sentiment and liquidity can flip quickly. Short‑term traders track every tick, while swing traders focus on whether Tenax Therapeutics Inc. can hold key support levels on the daily chart.
Conclusion
For traders studying TENX, the message is simple: respect the volatility and know the numbers. Tenax Therapeutics Inc. is burning over $14M in operating cash per quarter, with negative returns across the board, but it also holds more than $117M in cash and has no debt. That cushion gives TENX time, which is why the stock still commands a premium price‑to‑book multiple despite ongoing losses.
On the chart, TENX is a rollercoaster. The sharp dump from double digits into the low single digits intraday shows just how fast sentiment can flip when liquidity thins. After that, the consolidation around $2 and the broader drift down from the $16 area keep Tenax Therapeutics Inc. squarely in the speculative trading bucket rather than the steady growth bucket.
For active traders, that’s not a bad thing. It just demands discipline. As Tim Sykes likes to remind his students, “The market doesn’t care about your opinion, only your preparation and your rules.” That focus on preparation is echoed across many trading educators; as Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”. TENX rewards those who plan entries and exits, cut losses quickly, and size properly. Whether Tenax Therapeutics Inc. offers another spike or a slow bleed from here, the edge will belong to traders who treat this stock as a trading vehicle, not a promise.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.